Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.

[1]  R. Medcalf,et al.  Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. , 2005, Biochemical and biophysical research communications.

[2]  M. Russell,et al.  Cardiomyocyte-Specific Knockout and Agonist of Peroxisome Proliferator–Activated Receptor-γ Both Induce Cardiac Hypertrophy in Mice , 2005, Circulation research.

[3]  L. Iversen,et al.  Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo , 2005, Toxicologic pathology.

[4]  Jennifer Y. Liu,et al.  Pioglitazone initiation and subsequent hospitalization for congestive heart failure , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[5]  Reena Rao,et al.  Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.

[6]  H. Krumholz,et al.  Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. , 2005, Diabetes care.

[7]  N. Chalasani,et al.  Effect of Rosiglitazone on Serum Liver Biochemistries in Diabetic Patients with Normal and Elevated Baseline Liver Enzymes , 2005, The American Journal of Gastroenterology.

[8]  T. Kurtz.  Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator , 2005, Acta Diabetologica.

[9]  P. Nilsson.  Diabetes and obesity: new data on mechanisms and intervention trials , 2005, Expert review of cardiovascular therapy.

[10]  C. Long,et al.  PPAR-γ activation fails to provide myocardial protection in ischemia and reperfusion in pigs , 2005 .

[11]  K. Wassermann,et al.  The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats , 2005 .

[12]  B. McDermott,et al.  Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy. , 2005, European journal of pharmacology.

[13]  V. D. Hsu,et al.  Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program , 2005, Pharmacoepidemiology and drug safety.

[14]  Y. Higaki,et al.  High lipoprotein lipase activity increases insulin sensitivity in transgenic rabbits. , 2005, Metabolism: clinical and experimental.

[15]  P. Raskin,et al.  Thiazolidinediones and Insulin , 2005, Treatments in endocrinology.

[16]  Aravindan Kolandaivelu,et al.  Pioglitazone-induced heart failure despite normal left ventricular function. , 2004, The American journal of medicine.

[17]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[18]  R. Czekay,et al.  Unexpected Role of Plasminogen Activator Inhibitor 1 in Cell Adhesion and Detachment , 2004, Experimental biology and medicine.

[19]  M. Herregods,et al.  Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-&agr; and Peroxisome Proliferator–Activated Receptor-&ggr; Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice , 2004, Circulation.

[20]  M. Cooper.  The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. , 2004, American journal of hypertension.

[21]  S. Doggrell.  Telmisartan – killing two birds with one stone , 2004, Expert opinion on pharmacotherapy.

[22]  J. Sowers,et al.  Insights into the biology of diabetic vascular disease: what's new? , 2004, American journal of hypertension.

[23]  H. Münzberg,et al.  Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. , 2004, Endocrinology.

[24]  R. Tozawa,et al.  Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. , 2004, Biochemical and biophysical research communications.

[25]  O. Gavrilova,et al.  Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. , 2004, Endocrinology.

[26]  A. Tsatsoulis,et al.  The edematogenic properties of insulin. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  Jeremy W Tomlinson,et al.  11 (cid:1) -Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response , 2004 .

[28]  R. Rosenson,et al.  Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. , 2004, Clinical therapeutics.

[29]  T. Marcy,et al.  Second-Generation Thiazolidinediones and Hepatotoxicity , 2004, The Annals of pharmacotherapy.

[30]  I. Goldberg,et al.  Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk , 2004, Current atherosclerosis reports.

[31]  Lingyun Wu,et al.  Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. , 2004, American journal of hypertension.

[32]  J. Sheehan,et al.  Fasting hyperglycemia: etiology, diagnosis, and treatment. , 2004, Diabetes technology & therapeutics.

[33]  S. Welle,et al.  Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. , 2004, American journal of physiology. Endocrinology and metabolism.

[34]  R. MacIsaac,et al.  Thiazolidinediones and congestive heart failure—exacerbation or new onset of left ventricular dysfunction? , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[35]  C. Yosefy,et al.  Rosiglitazone Improves, While Glibenclamide Worsens Blood Pressure Control in Treated Hypertensive Diabetic and Dyslipidemic Subjects via Modulation of Insulin Resistance and Sympathetic Activity , 2004, Journal of cardiovascular pharmacology.

[36]  Cunegundo M Vergara,et al.  Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[37]  M. Quon,et al.  Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. , 2004, Molecular endocrinology.

[38]  B. Monia,et al.  Role of resistin in diet-induced hepatic insulin resistance. , 2004, The Journal of clinical investigation.

[39]  T. Ohshima,et al.  Transcriptional Activity of Peroxisome Proliferator-activated Receptor γ Is Modulated by SUMO-1 Modification* , 2004, Journal of Biological Chemistry.

[40]  C. Thiemermann.  Ligands of the peroxisome proliferator‐activated receptor‐γ and heart failure , 2004 .

[41]  J. Zierath,et al.  Sending the signal: molecular mechanisms regulating glucose uptake. , 2004, Medicine and science in sports and exercise.

[42]  A. Palmieri,et al.  Maternal MTHFR variant forms increase the risk in offspring of isolated nonsyndromic cleft lip with or without cleft palate , 2004, Human mutation.

[43]  G. Bray,et al.  The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. , 2004, Diabetes care.

[44]  Marjolein Visser,et al.  Re: "Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men". , 2004, American journal of epidemiology.

[45]  E. Schleicher,et al.  Protein Kinase C-ζ-induced Phosphorylation of Ser318 in Insulin Receptor Substrate-1 (IRS-1) Attenuates the Interaction with the Insulin Receptor and the Tyrosine Phosphorylation of IRS-1* , 2004, Journal of Biological Chemistry.

[46]  M. Lazar,et al.  Peroxisome proliferator-activated receptor γ in diabetes and metabolism , 2004 .

[47]  I. Juhan-vague,et al.  Contribution of PAI-1 in cardiovascular pathology. , 2004, Archives des maladies du coeur et des vaisseaux.

[48]  J. Seufert,et al.  A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. , 2004, Clinical therapeutics.

[49]  L. J. Hardies,et al.  Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients , 2004, International Journal of Obesity.

[50]  Donald D Hensrud,et al.  Splanchnic lipolysis in human obesity. , 2004, The Journal of clinical investigation.

[51]  M. Roden.  How free fatty acids inhibit glucose utilization in human skeletal muscle. , 2004, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[52]  S. Sassa,et al.  Heme oxygenase-1: a novel therapeutic target in oxidative tissue injuries. , 2004, Current medicinal chemistry.

[53]  P. Arner,et al.  Targets for TNF-α-induced lipolysis in human adipocytes , 2004 .

[54]  Robert Elashoff,et al.  Coronary Vasomotor Abnormalities in Insulin-Resistant Individuals , 2004, Annals of Internal Medicine.

[55]  K. Wellen,et al.  Interaction of Tumor Necrosis Factor-α- and Thiazolidinedione-Regulated Pathways in Obesity , 2004 .

[56]  T. Funahashi,et al.  Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina , 2004, Thrombosis and Haemostasis.

[57]  I. G. Fantus,et al.  Thiazolidinedione-Induced Congestive Heart Failure , 2004, The Annals of pharmacotherapy.

[58]  A. Bonen,et al.  Regulation of fatty acid transport by fatty acid translocase/CD36 , 2004, The Proceedings of the Nutrition Society.

[59]  R. Lerch,et al.  Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression and translocation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  M. Eren,et al.  Tumor Necrosis Factor α Activates the Human Plasminogen Activator Inhibitor-1 Gene through a Distal Nuclear Factor κB Site* , 2004, Journal of Biological Chemistry.

[61]  M. Lorenzo,et al.  Tumor Necrosis Factor α Produces Insulin Resistance in Skeletal Muscle by Activation of Inhibitor κB Kinase in a p38 MAPK-dependent Manner* , 2004, Journal of Biological Chemistry.

[62]  R. Willette,et al.  Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. , 2004, Cardiovascular research.

[63]  J. Flier,et al.  Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. , 2004, Diabetes.

[64]  S. Borst.  The role of TNF-α in insulin resistance , 2004 .

[65]  M. Evans,et al.  Lifestyle intervention or treatment with metformin. Which delays onset of type 2 diabetes? , 2004, Canadian family physician Medecin de famille canadien.

[66]  Melissa M. Parker,et al.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study: response to Delea et al. , 2004, Diabetes care.

[67]  D. Dazzi,et al.  Pioglitazone reduces blood pressure in non-dipping diabetic patients. , 2004, Minerva endocrinologica.

[68]  S. Mathur,et al.  PPAR&ggr; Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice , 2004, Hypertension.

[69]  C. Bode,et al.  Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones , 2004, Thrombosis and Haemostasis.

[70]  A. Greenberg,et al.  Adipocytokines and insulin resistance. , 2004, The Journal of clinical endocrinology and metabolism.

[71]  T. Meriden.  Progress with thiazolidinediones in the management of type 2 diabetes mellitus. , 2004, Clinical therapeutics.

[72]  J. Verbalis,et al.  Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats , 2004, Journal of Pharmacology and Experimental Therapeutics.

[73]  O. McGuinness,et al.  Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. , 2004, Diabetes.

[74]  C. Fernández-Galaz,et al.  Leptin impairs insulin signaling in rat adipocytes. , 2004, Diabetes.

[75]  Byung-Hyun Park,et al.  Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. , 2004, Biochemical and biophysical research communications.

[76]  Frank Hu,et al.  Coffee Consumption and Risk for Type 2 Diabetes Mellitus , 2004, Annals of Internal Medicine.

[77]  T. Ishihara,et al.  An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats , 2004, Clinical and experimental pharmacology & physiology.

[78]  C. Thiemermann.  Ligands of the peroxisome proliferator‐activated receptor‐γ and heart failure , 2004 .

[79]  P. Galuppo,et al.  Peroxisome proliferator activated‐receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction , 2004, British journal of pharmacology.

[80]  A. Dobrian,et al.  Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity , 2004, Hypertension.

[81]  S. Grundy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association , 2003, Diabetes care.

[82]  L. Ragolia,et al.  Protein phosphatase-1 and insulin action , 1998, Molecular and Cellular Biochemistry.

[83]  B. Rodrigues,et al.  Metabolic disturbances in diabetic cardiomyopathy , 1998, Molecular and Cellular Biochemistry.

[84]  J. Putten,et al.  Corticosteroids as long-term regulators of the insulin effectiveness in mouse 3T3 adipocytes , 1985, Diabetologia.

[85]  R. Denton,et al.  A partial view of the mechanism of insulin action , 1981, Diabetologia.

[86]  J. Carvalheira,et al.  Regulation of Cbl-associated protein/Cbl pathway in muscle and adipose tissues of two animal models of insulin resistance. , 2004, Endocrinology.

[87]  M. O’connor,et al.  Peroxisome Proliferator Activator Receptor-γ Ligands, 15-Deoxy-Δ12,14-Prostaglandin J2 and Ciglitazone, Reduce Systemic Inflammation in Polymicrobial Sepsis by Modulation of Signal Transduction Pathways 1 , 2003, The Journal of Immunology.

[88]  V. Fonseca.  Effect of thiazolidinediones on body weight in patients with diabetes mellitus. , 2003, The American journal of medicine.

[89]  N. Hollenberg.  Considerations for management of fluid dynamic issues associated with thiazolidinediones. , 2003, The American journal of medicine.

[90]  J. Serratosa,et al.  Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. , 2003, Human molecular genetics.

[91]  Stephen A. Smith,et al.  Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. , 2003, The Journal of clinical endocrinology and metabolism.

[92]  J. Capeau,et al.  Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. , 2003, Biochemical and biophysical research communications.

[93]  U. Smith,et al.  Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-α, Overexpressed in Human Fat Cells from Insulin-resistant Subjects* , 2003, Journal of Biological Chemistry.

[94]  P. Drake,et al.  Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes , 2003 .

[95]  G. Wolf.  The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis. , 2003, Nutrition reviews.

[96]  D. Stein,et al.  Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. , 2003, Diabetes.

[97]  G. Oster,et al.  Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. , 2003, Diabetes care.

[98]  J. Berger,et al.  O-Arylmandelic acids as highly selective human PPAR α/γ agonists , 2003 .

[99]  K. Kaestner,et al.  Genetic Modulation of PPARγ Phosphorylation Regulates Insulin Sensitivity , 2003 .

[100]  R. Chakrabarti,et al.  Ragaglitazar: a novel PPARα & PPARγ agonist with potent lipid‐lowering and insulin‐sensitizing efficacy in animal models , 2003 .

[101]  K. Park,et al.  Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells. , 2003, Diabetes research and clinical practice.

[102]  S. Mudaliar,et al.  Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[103]  A. Saltiel,et al.  The Roles of Cbl-b and c-Cbl in Insulin-stimulated Glucose Transport* , 2003, Journal of Biological Chemistry.

[104]  A. Garg,et al.  Thiazolidinedione-associated congestive heart failure and pulmonary edema. , 2003, Mayo Clinic proceedings.

[105]  W. März,et al.  Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. , 2003, Diabetes care.

[106]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[107]  S. Tilghman,et al.  Glyceroneogenesis and the Triglyceride/Fatty Acid Cycle* , 2003, Journal of Biological Chemistry.

[108]  M. Matsuda,et al.  Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. , 2003, Diabetes.

[109]  Kieran Clarke,et al.  The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. , 2003, Cardiovascular research.

[110]  H. Lodish,et al.  Troglitazone Antagonizes Tumor Necrosis Factor-α-induced Reprogramming of Adipocyte Gene Expression by Inhibiting the Transcriptional Regulatory Functions of NF-κB* , 2003, Journal of Biological Chemistry.

[111]  Minghan Wang,et al.  Modulation of PPARγ activity with pharmaceutical agents: Treatment of insulin resistance and atherosclerosis , 2003, Journal of cellular biochemistry.

[112]  C. Long,et al.  Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. , 2003, Diabetes.

[113]  B. Hoogwerf,et al.  Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. , 2003, Journal of the American College of Cardiology.

[114]  F. Leonetti,et al.  Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. , 2003, Obesity research.

[115]  S. Verma,et al.  Glitazones and heart failure: critical appraisal for the clinician. , 2003, Circulation.

[116]  J. Redondo,et al.  Plasminogen activator inhibitor type‐1 inhibits insulin signaling by competing with αvβ3 integrin for vitronectin binding , 2003 .

[117]  P. J. Larsen,et al.  PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly , 2003 .

[118]  S. Gray,et al.  Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability , 2003, Diabetologia.

[119]  H. Imoto,et al.  Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents. , 2003, Chemical & pharmaceutical bulletin.

[120]  L. Rossetti,et al.  Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. , 2003, The Journal of clinical investigation.

[121]  Joanna D. Holbrook,et al.  Resistin is expressed in human macrophages and directly regulated by PPARγ activators , 2003 .

[122]  A. Marchetti,et al.  Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. , 2003, Clinical therapeutics.

[123]  M. Stolar,et al.  Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. , 2003, Clinical therapeutics.

[124]  G. Chrousos,et al.  Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. , 2003, The Journal of clinical endocrinology and metabolism.

[125]  G. Shulman,et al.  Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle* , 2002, The Journal of Biological Chemistry.

[126]  A. Takeshita,et al.  Pioglitazone, a Peroxisome Proliferator-Activated Receptor-&ggr; Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.

[127]  R. Mooney,et al.  Interleukin-6 induces cellular insulin resistance in hepatocytes. , 2002, Diabetes.

[128]  T. Golub,et al.  Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. , 2002, Diabetes.

[129]  K. Murphy,et al.  A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. , 2002, Diabetes care.

[130]  R. Hammer,et al.  Glyceroneogenesis comes of age , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[131]  H. Imoto,et al.  Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives. , 2002, Chemical & pharmaceutical bulletin.

[132]  R. A. Norman,et al.  The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. , 2002, Diabetes.

[133]  M. Lazar,et al.  A futile metabolic cycle activated in adipocytes by antidiabetic agents , 2002, Nature Medicine.

[134]  Jasmine Chen,et al.  Constitutive Activation of Peroxisome Proliferator-activated Receptor-γ Suppresses Pro-inflammatory Adhesion Molecules in Human Vascular Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[135]  T. Okura,et al.  Vascular Inflammation Is Negatively Autoregulated by Interaction Between CCAAT/Enhancer-Binding Protein-&dgr; and Peroxisome Proliferator-Activated Receptor-&ggr; , 2002, Circulation research.

[136]  B. Staels,et al.  The role of PPARs in atherosclerosis. , 2002, Trends in molecular medicine.

[137]  A. Eddy.  Plasminogen activator inhibitor-1 and the kidney. , 2002, American journal of physiology. Renal physiology.

[138]  H. Koistinen,et al.  Analysis of paradoxical observations on the association between leptin and insulin resistance , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[139]  S. Cuzzocrea,et al.  Ligands of the peroxisome proliferator‐activated receptors (PPAR‐γ and PPAR‐α) reduce myocardial infarct size , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[140]  T. Asano,et al.  Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. , 2002, Diabetes.

[141]  B. Staels,et al.  Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. , 2002, Diabetes.

[142]  S. Zuckerman,et al.  Peroxisome proliferator-activated receptor α,γ coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice , 2002, Lipids.

[143]  M. Jensen,et al.  Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[144]  Jiming Zhou,et al.  Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. , 2002, Biochemical and biophysical research communications.

[145]  K. Ogilvie,et al.  A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. , 2002, Diabetes.

[146]  K. Clarke,et al.  Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. , 2002, Diabetes.

[147]  H. Uozumi,et al.  Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In Vivo , 2002 .

[148]  E. Olson,et al.  Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism? , 2002, Circulation.

[149]  H. Lebovitz,et al.  Differentiating members of the thiazolidinedione class: a focus on safety , 2002, Diabetes/metabolism research and reviews.

[150]  S. Matsukura,et al.  Early events involved in the development of insulin resistance in Zucker fatty rat , 2002, International Journal of Obesity.

[151]  Vincent Lebon,et al.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. , 2002, Diabetes.

[152]  S. O’Rahilly,et al.  Induction of Adipocyte Complement-related Protein of 30 Kilodaltons by Ppar␥ Agonists: a Potential Mechanism of Insulin Sensitization , 2022 .

[153]  M. Lazar,et al.  The Dawn of the SPPARMs? , 2002, Science's STKE.

[154]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[155]  Lee-Ming Chuang,et al.  Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. , 2002, Diabetes care.

[156]  S. Tilghman,et al.  A mutation in the peroxisome proliferator-activated receptor γ-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[157]  F. Lönnqvist,et al.  Mapping of Early Signaling Events in Tumor Necrosis Factor-α-mediated Lipolysis in Human Fat Cells* , 2002, The Journal of Biological Chemistry.

[158]  D. S. Worrall,et al.  Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. , 2002, The Journal of clinical endocrinology and metabolism.

[159]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[160]  D. Moller,et al.  New drug targets for type 2 diabetes and the metabolic syndrome , 2001, Nature.

[161]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[162]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[163]  J. Flier,et al.  A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.

[164]  M. Kohno,et al.  Pioglitazone Improves Left Ventricular Diastolic Function and Decreases Collagen Accumulation in Prediabetic Stage of a Type II Diabetic Rat , 2001, Journal of cardiovascular pharmacology.

[165]  L. Teboul,et al.  Structural and functional characterization of the mouse fatty acid translocase promoter: activation during adipose differentiation. , 2001, The Biochemical journal.

[166]  N. Barzilai,et al.  Overfeeding rapidly induces leptin and insulin resistance. , 2001, Diabetes.

[167]  W. Bao,et al.  In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-&ggr; Agonist Rosiglitazone , 2001, Circulation.

[168]  Y. Terauchi,et al.  The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance* , 2001, The Journal of Biological Chemistry.

[169]  John J. Mullins,et al.  Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11β-Hydroxysteroid Dehydrogenase Type 1 Null Mice* , 2001, The Journal of Biological Chemistry.

[170]  C. Drevon,et al.  Inhibition by insulin of resistin gene expression in 3T3‐L1 adipocytes , 2001, FEBS letters.

[171]  B. Spiegelman,et al.  PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.

[172]  Richard T. Lee,et al.  Peroxisome Proliferator-Activated Receptor &ggr; Activators Inhibit Cardiac Hypertrophy in Cardiac Myocytes , 2001, Circulation.

[173]  G. Sesti,et al.  Defects of the insulin receptor substrate (IRS) system in human metabolic disorders , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[174]  S. Verma,et al.  Insulin Action in the Vasculature: Physiology and Pathophysiology , 2001, Journal of Vascular Research.

[175]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[176]  T. Tai,et al.  Molecular scanning of the human sorbin and SH3-domain-containing-1 (SORBS1) gene: positive association of the T228A polymorphism with obesity and type 2 diabetes. , 2001, Human molecular genetics.

[177]  D. Loskutoff,et al.  Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[178]  G. Shulman,et al.  Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. , 2001, Genes & development.

[179]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[180]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.

[181]  M. Roden.  Non-invasive studies of glycogen metabolism in human skeletal muscle using nuclear magnetic resonance spectroscopy , 2001, Current opinion in clinical nutrition and metabolic care.

[182]  S. Kushibiki,et al.  Insulin resistance induced in dairy steers by tumor necrosis factor alpha is partially reversed by 2,4-thiazolidinedione. , 2001, Domestic animal endocrinology.

[183]  P. Raskin,et al.  A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. , 2001, Diabetes care.

[184]  G. Schmitz,et al.  Adipophilin is a sensitive marker for lipid loading in human blood monocytes. , 2001, Biochimica et biophysica acta.

[185]  T. Sasaoka,et al.  Pioglitazone Ameliorates Tumor Necrosis Factor-α–Induced Insulin Resistance by a Mechanism Independent of Adipogenic Activity of Peroxisome Proliferator–Activated Receptor-γ , 2001 .

[186]  M. Velussi.  MCC-555 (Mitsubishi-Tokyo Pharmaceuticals). , 2001, IDrugs : the investigational drugs journal.

[187]  M. Cooper,et al.  Regulation of Expression of 11b-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines* , 2001 .

[188]  R. Thieringer,et al.  Peroxisome Proliferator-activated Receptor-γ Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity* , 2001, The Journal of Biological Chemistry.

[189]  S. Kalhan,et al.  Glyceroneogenesis and the Source of Glycerol for Hepatic Triacylglycerol Synthesis in Humans* , 2001, The Journal of Biological Chemistry.

[190]  H. Sul,et al.  A Cysteine-rich Adipose Tissue-specific Secretory Factor Inhibits Adipocyte Differentiation* , 2001, The Journal of Biological Chemistry.

[191]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[192]  M. Stewart,et al.  Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. , 2001, BMJ.

[193]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[194]  K. Ueki,et al.  Insulin Receptor Substrate 3 (IRS-3) and IRS-4 Impair IRS-1- and IRS-2-Mediated Signaling , 2001, Molecular and Cellular Biology.

[195]  E. Mayer-Davis,et al.  Obesity and sedentary lifestyle: Modifiable risk factors for prevention of type 2 diabetes , 2001, Current diabetes reports.

[196]  A. Saltiel,et al.  The role of protein phosphatase-1 in insulin action. , 2001, Recent progress in hormone research.

[197]  R. Watson,et al.  Intracellular organization of insulin signaling and GLUT4 translocation. , 2001, Recent progress in hormone research.

[198]  C. Rondinone,et al.  Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. , 2001, Diabetes.

[199]  B. Wajchenberg.  Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. , 2000, Endocrine reviews.

[200]  R. Ahima,et al.  Adipose Tissue as an Endocrine Organ , 2006, Obesity.

[201]  M. Daly,et al.  Guilt by association , 2000, Nature Genetics.

[202]  Eric S. Lander,et al.  The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.

[203]  E. Bruckert,et al.  Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. , 2000, The Journal of clinical endocrinology and metabolism.

[204]  F. Peale,et al.  FIZZ1, a novel cysteine‐rich secreted protein associated with pulmonary inflammation, defines a new gene family , 2000, The EMBO journal.

[205]  U. Boelsterli,et al.  Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. , 2000, Biochemical pharmacology.

[206]  R. Dina,et al.  Angiotensin II-receptor antagonists: an overview. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[207]  X. Shen,et al.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. , 2000, Diabetes.

[208]  A. Saltiel,et al.  Cloning and Characterization of a Functional Peroxisome Proliferator Activator Receptor-γ-responsive Element in the Promoter of the CAP Gene* , 2000, The Journal of Biological Chemistry.

[209]  Roger Davis,et al.  The c-Jun NH2-terminal Kinase Promotes Insulin Resistance during Association with Insulin Receptor Substrate-1 and Phosphorylation of Ser307 * , 2000, The Journal of Biological Chemistry.

[210]  G. Schwartz,et al.  Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. , 2000, Circulation.

[211]  S. Haffner,et al.  Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. , 2000, Circulation.

[212]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[213]  B. Spiegelman,et al.  A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor γ Inhibits Adipocyte Differentiation* , 2000, The Journal of Biological Chemistry.

[214]  A. Saltiel.  Series introduction: the molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. , 2000, The Journal of clinical investigation.

[215]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[216]  G. Shulman,et al.  On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .

[217]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .

[218]  J. Corton,et al.  Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. , 2000, Annual review of pharmacology and toxicology.

[219]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[220]  T. Osumi,et al.  Characterization of the Amino-terminal Activation Domain of Peroxisome Proliferator-activated Receptor α , 1999, The Journal of Biological Chemistry.

[221]  P. Pilch,et al.  Role of PPARγ in Regulating Adipocyte Differentiation and Insulin‐Responsive Glucose Uptake , 1999, Annals of the New York Academy of Sciences.

[222]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[223]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[224]  R. Hammer,et al.  Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy , 1999, Nature.

[225]  M. Kodama,et al.  Troglitazone inhibits bicarbonate secretion in rat and human duodenum. , 1999, The Journal of pharmacology and experimental therapeutics.

[226]  M. Quon,et al.  Insulin stimulates both endothelin and nitric oxide activity in the human forearm. , 1999, Circulation.

[227]  S. Wannamethee,et al.  Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. , 1999, Diabetes care.

[228]  J. Auwerx.  PPARγ, the ultimate thrifty gene , 1999, Diabetologia.

[229]  T. Ishida,et al.  Thiazolidinedione inhibits the production of monocyte chemoattractant protein‐1 in cytokine‐treated human vascular endothelial cells , 1999, FEBS letters.

[230]  T. Ishida,et al.  Thiazolidinedione inhibits production of RANTES in a cytokine‐treated human lung epithelial cell line , 1999, FEBS letters.

[231]  G. Shulman,et al.  Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. , 1999, Diabetes.

[232]  J. Lehmann,et al.  A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[233]  T. Watanabe,et al.  Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. , 1999, Biochemical and biophysical research communications.

[234]  A. Burger,et al.  Regulation of the Transcriptional Activity of the Peroxisome Proliferator-activated Receptor α by Phosphorylation of a Ligand-independent trans-Activating Domain* , 1999, The Journal of Biological Chemistry.

[235]  P. Pilch,et al.  Reconstitution of Insulin-sensitive Glucose Transport in Fibroblasts Requires Expression of Both PPARγ and C/EBPα* , 1999, The Journal of Biological Chemistry.

[236]  B. Frohnert,et al.  Identification of a Functional Peroxisome Proliferator-responsive Element in the Murine Fatty Acid Transport Protein Gene* , 1999, The Journal of Biological Chemistry.

[237]  D L Rothman,et al.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.

[238]  J. H. Johnson,et al.  Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[239]  P. J. Randle,et al.  Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. , 1998, Diabetes/metabolism reviews.

[240]  Y. Yazaki,et al.  A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. , 1998, Diabetes.

[241]  M. Lazar,et al.  Interdomain communication regulating ligand binding by PPAR-γ , 1998, Nature.

[242]  L. Jendeberg,et al.  Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ* , 1998, The Journal of Biological Chemistry.

[243]  J. Lehmann,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.

[244]  J. Auwerx,et al.  PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter , 1998 .

[245]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[246]  N. Sato,et al.  Troglitazone Reduces Plasma Leptin Concentration but Increases Hunger in NIDDM Patients , 1998, Diabetes Care.

[247]  K. Siddle,et al.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. , 1998, The Biochemical journal.

[248]  C. Tack,et al.  Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects , 1998, Diabetes Care.

[249]  R. Tsien,et al.  Membrane-permeant Esters of Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[250]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[251]  T. Buchanan,et al.  TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. , 1998, Controlled clinical trials.

[252]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[253]  M. Benito,et al.  Tumor Necrosis Factor-α Causes Insulin Receptor Substrate-2-Mediated Insulin Resistance and Inhibits Insulin-Induced Adipogenesis in Fetal Brown Adipocytes. , 1998, Endocrinology.

[254]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[255]  H. Sul,et al.  Understanding adipocyte differentiation. , 1998, Physiological reviews.

[256]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[257]  R. Komers,et al.  THIAZOLIDINEDIONES: TOOLS FOR THE RESEARCH OF METABOLIC SYNDROME X , 1998 .

[258]  Z. Wu,et al.  PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. , 1998, The Journal of clinical investigation.

[259]  Edwards,et al.  11 b-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress , 1997 .

[260]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[261]  D. Leroith,et al.  A Molecular Basis for Insulin Resistance , 1997, The Journal of Biological Chemistry.

[262]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[263]  A. Saltiel,et al.  Insulin stimulates tyrosine phosphorylation of the proto-oncogene product of c-Cbl in 3T3-L1 adipocytes. , 1997, The Biochemical journal.

[264]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[265]  G. Shulman,et al.  13C and 31P NMR Studies on the Effects of Increased Plasma Free Fatty Acids on Intramuscular Glucose Metabolism in the Awake Rat* , 1997, The Journal of Biological Chemistry.

[266]  U. Smith,et al.  Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[267]  L. Hamann,et al.  Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists , 1997, Nature.

[268]  Julio E. Pérez,et al.  Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.

[269]  Roy J Martin,et al.  Evidence for a Central Mechanism of Obesity in the Zucker Rat: Role of Neuropeptide Y and Leptin 1 , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[270]  M. Lazar,et al.  Transcriptional Activation by Peroxisome Proliferator-activated Receptor γ Is Inhibited by Phosphorylation at a Consensus Mitogen-activated Protein Kinase Site* , 1997, The Journal of Biological Chemistry.

[271]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[272]  J. Stephens,et al.  Tumor Necrosis Factor-α-induced Insulin Resistance in 3T3-L1 Adipocytes Is Accompanied by a Loss of Insulin Receptor Substrate-1 and GLUT4 Expression without a Loss of Insulin Receptor-mediated Signal Transduction* , 1997, The Journal of Biological Chemistry.

[273]  B. Goldstein,et al.  Effect of tumor necrosis factor‐α on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein‐tyrosine phosphatases , 1997 .

[274]  M. D. Leibowitz,et al.  Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. , 1996, Endocrinology.

[275]  P. Pekala,et al.  Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. , 1996, The Biochemical journal.

[276]  J. Auwerx,et al.  Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. , 1996, The Journal of clinical investigation.

[277]  Z. Wu,et al.  Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids , 1996, Molecular and cellular biology.

[278]  M. D. Leibowitz,et al.  Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2 , 1996 .

[279]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[280]  K. Petersen,et al.  Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.

[281]  M. Lazar,et al.  Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[282]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[283]  E. Shafrir,et al.  Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. , 1996, Diabetes & metabolism.

[284]  C. Roberts,et al.  Interaction between the Insulin Receptor and Its Downstream Effectors , 1996, The Journal of Biological Chemistry.

[285]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[286]  J. Lehmann,et al.  The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .

[287]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[288]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[289]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[290]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[291]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[292]  M. Papa,et al.  Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. , 1995, The Journal of biological chemistry.

[293]  N. Copeland,et al.  Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. , 1995, European journal of biochemistry.

[294]  Z. Wu,et al.  Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis. , 1995, Genes & development.

[295]  T. Buchanan,et al.  Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. , 1995, The Journal of clinical investigation.

[296]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[297]  D. Fabbro,et al.  PKC zeta is a molecular switch in signal transduction of TNF‐alpha, bifunctionally regulated by ceramide and arachidonic acid. , 1995, The EMBO journal.

[298]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[299]  R. Shulman,et al.  Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[300]  R. Kahn.  Causes of insulin resistance , 1995, Nature.

[301]  S. McKnight,et al.  Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. , 1995, Genes & development.

[302]  B. Spiegelman,et al.  PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene , 1995, Molecular and cellular biology.

[303]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[304]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[305]  B. Spiegelman,et al.  Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. , 1994, The Journal of clinical investigation.

[306]  N. Ruderman,et al.  The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. , 1994, The Journal of biological chemistry.

[307]  J. Sowers,et al.  Effects of pioglitazone on calcium channels in vascular smooth muscle. , 1994, Hypertension.

[308]  M. Kasuga,et al.  Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. , 1994, The Biochemical journal.

[309]  A. Brasier,et al.  Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. , 1994, Endocrinology.

[310]  B. Spiegelman,et al.  Tumor necrosis factor alpha inhibits signaling from the insulin receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[311]  C. Kahn,et al.  The insulin signaling system. , 1994, The Journal of biological chemistry.

[312]  E. Ravussin,et al.  Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. , 1993, The New England journal of medicine.

[313]  Y. Ebina,et al.  Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. , 1993, Biochemical and biophysical research communications.

[314]  M. Quon,et al.  Use of bismannose photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells. Evidence that exocytosis is a critical site of hormone action. , 1993, The Journal of biological chemistry.

[315]  T. Kadowaki,et al.  Normal insulin receptor substrate-1 phosphorylation in autophosphorylation-defective truncated insulin receptor. Evidence that phosphorylation of substrates might be sufficient for certain biological effects evoked by insulin. , 1993, The Journal of biological chemistry.

[316]  A. Mahfoudi,et al.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[317]  G. Holman,et al.  Comparison of GLUT4 and GLUT1 subcellular trafficking in basal and insulin-stimulated 3T3-L1 cells. , 1993, The Journal of biological chemistry.

[318]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[319]  I. Issemann,et al.  The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. , 1993, Biochimie.

[320]  B. Jhun,et al.  Effects of insulin on steady state kinetics of GLUT4 subcellular distribution in rat adipocytes. Evidence of constitutive GLUT4 recycling. , 1992, The Journal of biological chemistry.

[321]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[322]  R. Nordan,et al.  Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. , 1992, Cancer research.

[323]  J. Stephens,et al.  Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. , 1992, The Journal of biological chemistry.

[324]  R. Shulman,et al.  31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. , 1992, The Journal of clinical investigation.

[325]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[326]  R. DeFronzo,et al.  Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.

[327]  C H Lang,et al.  Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. , 1992, Endocrinology.

[328]  S. Enerbäck,et al.  The CCAAT/enhancer binding protein and its role in adipocyte differentiation: evidence for direct involvement in terminal adipocyte development. , 1991, The EMBO journal.

[329]  J. Stephens,et al.  Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. , 1991, The Journal of biological chemistry.

[330]  A. Vaag,et al.  Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. , 1991, The Journal of clinical investigation.

[331]  R. Umek,et al.  Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. , 1991, Genes & development.

[332]  M. Mozzoli,et al.  Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. , 1991, The Journal of clinical investigation.

[333]  C. Kahn,et al.  Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein , 1991, Nature.

[334]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[335]  C. Grunfeld,et al.  Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities. , 1990, Advances in internal medicine.

[336]  R. Roth,et al.  Insulin receptor structure and function in normal and pathological conditions. , 1990, Annual review of medicine.

[337]  H. Horikoshi,et al.  Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. , 1989, Journal of medicinal chemistry.

[338]  Yii-Der I. Chen,et al.  Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM , 1988, Diabetes.

[339]  B V Howard,et al.  Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. , 1988, The New England journal of medicine.

[340]  C. Kahn,et al.  A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. , 1988, The Journal of biological chemistry.

[341]  O. Rosen,et al.  Increasing the cAMP content of IM-9 cells alters the phosphorylation state and protein kinase activity of the insulin receptor. , 1986, The Journal of biological chemistry.

[342]  M. Rao,et al.  Peroxisome proliterators and cancer: mechanisms and implications , 1986 .

[343]  E. Van Obberghen,et al.  Two different protein kinase activities are associated with the insulin receptor. , 1983, The Biochemical journal.

[344]  G. Grunberger,et al.  Insulin stimulates phosphorylation of serine residues in soluble insulin receptors. , 1983, Biochemical and biophysical research communications.

[345]  H. Iwatsuka,et al.  Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent , 1983, Diabetes.

[346]  M. Cobb,et al.  Phosphorylation activates the insulin receptor tyrosine protein kinase. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[347]  C. Kahn,et al.  Insulin stimulation of phosphorylation of the beta subunit of the insulin receptor. Formation of both phosphoserine and phosphotyrosine. , 1982, The Journal of biological chemistry.

[348]  B. Jeanrenaud,et al.  Potential mechanism of insulin action on glucose transport in the isolated rat diaphragm. Apparent translocation of intracellular transport units to the plasma membrane. , 1981, The Journal of biological chemistry.

[349]  O. Rosen,et al.  Development of hormone receptors and hormonal responsiveness in vitro. Insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-L1 cells. , 1978, The Journal of biological chemistry.

[350]  J. Olefsky.  The effects of spontaneous obesity on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. , 1976, The Journal of clinical investigation.

[351]  H. Green,et al.  An established preadipose cell line and its differentiation in culture II. Factors affecting the adipose conversion , 1975, Cell.

[352]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.